Want to see PACB full AI Analyst Report?
Pacific Biosciences (PACB) Ratios
Pacific Biosciences Ratios
PACB's free cash flow for Q2 2026 was $-84.87M. For the 2026 fiscal year, PACB's free cash flow was decreased by $-4.60M and operating cash flow was $-80.27M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.89 | 7.48 | 7.81 | 3.24 | 15.36 |
| Quick Ratio | 5.99 | 6.59 | 7.21 | 3.04 | 15.01 |
| Cash Ratio | 1.17 | 0.84 | 1.89 | 1.23 | 6.42 |
| Solvency Ratio | -0.21 | -0.34 | -0.26 | -0.25 | -0.14 |
| Operating Cash Flow Ratio | -2.04 | -3.11 | -2.80 | -1.00 | -1.55 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -543.98 | -142.89 | -69.14 |
| Net Current Asset Value | $ -403.70M | $ -258.17M | $ -302.66M | $ -352.11M | $ -114.85M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.97 | 0.53 | 0.53 | 0.54 | 0.48 |
| Debt-to-Equity Ratio | 142.07 | 1.33 | 1.33 | 1.68 | 1.21 |
| Debt-to-Capital Ratio | 0.99 | 0.57 | 0.57 | 0.63 | 0.55 |
| Long-Term Debt-to-Capital Ratio | 0.99 | 0.56 | 0.56 | 0.61 | 0.53 |
| Financial Leverage Ratio | 146.58 | 2.49 | 2.49 | 3.14 | 2.54 |
| Debt Service Coverage Ratio | -22.00 | -18.12 | -17.51 | -17.07 | -11.11 |
| Interest Coverage Ratio | -80.18 | -35.36 | -23.32 | -20.91 | -16.79 |
| Debt to Market Cap | 1.25 | 1.29 | 0.36 | 0.49 | 0.22 |
| Interest Debt Per Share | 2.56 | 2.50 | 3.74 | 4.29 | 4.75 |
| Net Debt to EBITDA | -4.56 | -2.54 | -2.78 | -2.21 | -1.97 |
| Profitability Margins | |||||
| Gross Profit Margin | 31.67% | 24.21% | 26.32% | 38.22% | 45.10% |
| EBIT Margin | -336.93% | -192.27% | -151.51% | -233.48% | -201.01% |
| EBITDA Margin | -95.43% | -157.63% | -135.21% | -219.98% | -192.13% |
| Operating Profit Margin | -348.46% | -307.97% | -166.80% | -239.43% | -161.24% |
| Pretax Profit Margin | -341.28% | -200.98% | -158.67% | -244.92% | -210.61% |
| Net Profit Margin | -341.47% | -201.18% | -152.97% | -244.92% | -138.85% |
| Continuous Operations Profit Margin | -341.47% | -201.18% | -152.97% | -244.92% | -138.85% |
| Net Income Per EBT | 100.06% | 100.10% | 96.41% | 100.00% | 65.93% |
| EBT Per EBIT | 97.94% | 65.26% | 95.12% | 102.30% | 130.62% |
| Return on Assets (ROA) | -69.68% | -24.58% | -17.57% | -17.78% | -9.03% |
| Return on Equity (ROE) | -10214.54% | -61.16% | -43.74% | -55.83% | -22.91% |
| Return on Capital Employed (ROCE) | -76.41% | -39.72% | -20.26% | -20.43% | -10.87% |
| Return on Invested Capital (ROIC) | -76.37% | -39.39% | -19.41% | -20.28% | -7.13% |
| Return on Tangible Assets | -121.09% | -56.02% | -37.10% | -33.19% | -15.28% |
| Earnings Yield | -97.41% | -61.68% | -12.33% | -17.11% | -4.35% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.51 | 5.60 | 5.48 | 6.83 | 5.38 |
| Payables Turnover | 5.26 | 7.04 | 9.81 | 6.59 | 6.51 |
| Inventory Turnover | 2.22 | 1.99 | 2.61 | 1.57 | 2.91 |
| Fixed Asset Turnover | 2.43 | 3.31 | 2.91 | 1.58 | 1.65 |
| Asset Turnover | 0.20 | 0.12 | 0.11 | 0.07 | 0.07 |
| Working Capital Turnover Ratio | 0.43 | 0.29 | 0.32 | 0.16 | 0.19 |
| Cash Conversion Cycle | 176.06 | 197.07 | 169.46 | 230.04 | 137.06 |
| Days of Sales Outstanding | 80.86 | 65.23 | 66.65 | 53.44 | 67.79 |
| Days of Inventory Outstanding | 164.54 | 183.72 | 140.02 | 231.98 | 125.31 |
| Days of Payables Outstanding | 69.34 | 51.87 | 37.21 | 55.38 | 56.04 |
| Operating Cycle | 245.40 | 248.95 | 206.67 | 285.43 | 193.10 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.37 | -0.75 | -1.05 | -1.17 | -0.55 |
| Free Cash Flow Per Share | -0.38 | -0.77 | -1.09 | -1.25 | -0.58 |
| Dividend Paid and CapEx Coverage Ratio | -40.98 | -33.30 | -30.14 | -15.55 | -18.75 |
| Capital Expenditure Coverage Ratio | -40.98 | -33.30 | -30.14 | -15.55 | -18.75 |
| Operating Cash Flow Coverage Ratio | -0.15 | -0.31 | -0.29 | -0.28 | -0.12 |
| Operating Cash Flow to Sales Ratio | -0.70 | -1.34 | -1.33 | -2.05 | -0.85 |
| Free Cash Flow Yield | -20.31% | -42.25% | -11.07% | -15.25% | -2.81% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.03 | -1.62 | -8.11 | -5.85 | -22.99 |
| Price-to-Sales (P/S) Ratio | 3.51 | 3.26 | 12.41 | 14.32 | 31.92 |
| Price-to-Book (P/B) Ratio | 104.87 | 0.99 | 3.55 | 3.26 | 5.27 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.92 | -2.37 | -9.03 | -6.56 | -35.57 |
| Price-to-Operating Cash Flow Ratio | -5.04 | -2.44 | -9.33 | -6.98 | -37.47 |
| Price-to-Earnings Growth (PEG) Ratio | -0.02 | 0.24 | 0.60 | -0.10 | 0.04 |
| Enterprise Value Multiple | -8.23 | -4.61 | -11.96 | -8.72 | -18.59 |
| Enterprise Value | 1.26B | 1.12B | 3.24B | 2.46B | 4.66B |
| EV to EBITDA | -8.23 | -4.61 | -11.96 | -8.72 | -18.59 |
| EV to Sales | 7.86 | 7.27 | 16.17 | 19.17 | 35.71 |
| EV to Free Cash Flow | -11.03 | -5.27 | -11.77 | -8.78 | -39.80 |
| EV to Operating Cash Flow | -11.30 | -5.43 | -12.16 | -9.35 | -41.92 |
| Tangible Book Value Per Share | -1.09 | -0.73 | -0.86 | -1.15 | -0.15 |
| Shareholders’ Equity Per Share | 0.02 | 1.85 | 2.77 | 2.51 | 3.88 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | 0.04 | 0.00 | 0.34 |
| Revenue Per Share | 0.53 | 0.56 | 0.79 | 0.57 | 0.64 |
| Net Income Per Share | -1.82 | -1.13 | -1.21 | -1.40 | -0.89 |
| Tax Burden | 1.00 | 1.00 | 0.96 | 1.00 | 0.66 |
| Interest Burden | 1.01 | 1.05 | 1.05 | 1.05 | 1.05 |
| Research & Development to Revenue | 0.61 | 0.88 | 0.93 | 1.50 | 0.87 |
| SG&A to Revenue | 0.88 | 1.14 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.26 | 0.00 | 0.00 | 0.61 | 0.62 |
| Income Quality | 0.20 | 0.67 | 0.87 | 0.84 | 0.61 |
Currency in USD
